Founders Metals Hits 72.0 m of 2.29 g/t Gold at Van Gogh; Extends Mineralization from Surface to 200 m Vertical Depth
Highlights
Drill hole VG004 intercepts 72.0 m of 2.29 g/t Au from 177.0 m down hole (Figure 2)
Gold mineralization extended from surface (channel - 17.8 m of 5.68 g/t Au), through saprolite zone (VG001 - 28.5 m of 7.12 g/t Au), and into fresh rock down to 200.0 m vertical depth (VG004 - 72.0 m of 2.29 g/t Au)
Mineralized interval potentially broadens with depth from surface
Completely original discovery with no current or historical artisanal mining within 1.5 km of Van Gogh target area
With the success at Da Vinci and Van Gogh, Founders is committed to allocating up to 50% of its 2025 drill metres to high-priority targets in brand new areas
5 th diamond drill operational by mid-year
"The latest Van Gogh results further support the tier 1 discovery potential that Antino and our 2025 exploration program represents. Van Gogh is emerging as another key discovery, with characteristics most like Upper Antino," said Colin Padget, President & CEO. "Founders' focus this year is on unlocking the property's full potential and building value for shareholders through systematic discovery and the ongoing expansion of our earlier successes. To this end, we currently have four drills turning full-time and a fifth rig will be operational by mid-year."
Geology and Drilling Discussion
Van Gogh is 2.0 km from Lawa and 3.8 km from Da Vinci, and forms part of an emerging multi-kilometre northwest oriented gold trend extending through the Maria Geralda target to Lower Antino, and sub-parallel to the main Antino Shear Zone spanning 15+ km from Upper Antino to Da Vinci (Figure 1). Gold mineralization at Van Gogh is hosted within a subvertical mylonite zone with estimated true widths ranging ~25-50+ metres. The mineralized zones comprise broad intervals of intensely sheared, highly silicified country rock containing multiple generations of quartz veining.
In VG004, the gold-bearing intervals contain up to 15% sulphide (pyrite) and coincide with moderate to strong sericite-chlorite-ankerite alteration.
Drill holes VG002 and VG003 were drilled to test the along-strike continuity of the saprolite (oxide)-hosted gold mineralization from previously reported channel (17.8 m of 5.68 g/t Au) and drilling (VG001, 28.5 m of 7.12 g/t Au) results but are interpreted to have gone over the top of the mineralized structure. VG002 and VG003 logging shows similar broad-scale shearing to that observed deeper in holes VG001 and VG004, however lacked the characteristic sulphide content commonly associated with significant gold mineralization at Antino. In VG004, the steeply dipping gold mineralization occurs in fresh rock over a much broader interval than in the saprolite above (Figure 2), which may have been transported (i.e., slumped) several metres downslope. Follow-up drilling focuses on extending the broad, fresh rock, gold-bearing interval VG004 and incorporates newly acquired downhole structural and surficial mapping data.
About Founders Metals Inc.
Founders Metals is a Canadian-based exploration company focused on advancing the Antino Gold Project located in Suriname, South America, in the heart of the Guiana Shield. Antino is 20,000 hectares and has produced over 500,000 ounces of gold from surface and alluvial mining to date 1. The Company is fully financed for up to 60,000 metres of drilling in 2025.
1 2022 Technical Report - Antino Project; Suriname, South America. K. Raffle, BSc, P. Geo & Rock Lefrançois, BSc, P.Geo.
Table 1: Drill Hole Assay Results
Hole ID From (m) To (m) Interval* (m) Au (g/t)
VG004 177.0 249.0 72.0 2.29
and 262.0 271.0 9.0 1.51
VG003 NSA
VG002 NSA
*Intervals are down-hole depths. True widths of mineralization are estimated to be approximately 85% of the down-hole interval based on preliminary results and observations.
Table 2: Drill Hole Location
Hole ID Easting (m) Northing (m) Elevation (m) Azimuth (°) Dip (°) Depth (m)
VG004 828148.7 395941.3 151.0 259.7 -55.1 343.9
VG003 828066.3 395866.5 135.6 80.0 -49.9 284.1
VG002 828013.0 395949.0 115.2 79.9 -50.1 251.0
The coordinate reference system is WGS 84, UTM zone 21N (EPSG 32621)
Figure 1: Property Scale Map with Auger Samples and Van Gogh Drilling Results
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7574/244795_plan%20map1.png
Figure 2: Van Gogh Cross-Section
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7574/244795_e8e02d3c04668ad6_002full.jpg
Figure 3: Van Gogh Core Photos
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7574/244795_e8e02d3c04668ad6_003full.jpg
Core photos of Van Gogh drill hole VG004 showing excellent grade distribution throughout the interval from 177.0 m (upper left, left column) to 249.0 m (bottom right, right column).
Quality Assurance and Control
Samples were analyzed at FILAB Suriname, a Bureau Veritas Certified Laboratory in Paramaribo, Suriname (a commercial certified laboratory under ISO 9001:2015). Samples are crushed to 75% passing 2.35 mm screen, riffle split (700 g) and pulverized to 85% passing 88 µm. Samples were analyzed using a 50 g fire assay (50 g aliquot) with an Atomic Absorption (AA) finish. For samples that return assay values over 5.0 grams per tonne (g/t), another cut was taken from the original pulp and fire assayed with a gravimetric finish. Founders Metals inserts blanks and certified reference standards in the sample sequence for quality control. External QA-QC checks are performed at ALS Global Laboratories (Geochemistry Division) in Lima, Peru (an ISO/IEC 17025:2017 accredited facility). A secure chain of custody is maintained in transporting and storing of all samples. Drill intervals with visible gold are assayed using metallic screening. Rock chip samples from outcrop/bedrock are selective by nature and may not be representative of the mineralization hosted on the project.
Qualified Persons
The technical content of this news release has been reviewed and approved by Michael Dufresne, M.Sc., P.Geol., P.Geo., a qualified person as defined by National Instrument 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS,
Per:" Colin Padget"
Colin Padget
President, Chief Executive Officer, and Director
Contact Information
Katie MacKenzie, Vice President, Corporate Development
Tel: 306 537 8903 | katiem@fdrmetals.com
Cautionary Statement Regarding Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the use of proceeds from the Company's recently completed financings and the future or prospects of the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect ", "is expected ", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management discussion and analysis. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.
All material information on Founders Metals can be found at www.sedarplus.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
9 hours ago
- Toronto Star
Prime Drink Group Provides Bi-Weekly MCTO Status Report and Announces Closing of Private Placement
MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) ('Prime' or the 'Company') announces that further to its news release date July 30, 2025, the Company voluntarily applied for and the Company's principal regulator, the British Columbia Securities Commission (the 'BCSC') granted a management cease trade order (the 'MCTO') dated July 30, 2025, under National Policy 12-203 Management Cease Trade Orders ('NP 12-203') and provided the Company with an extension to file its annual financial statements for the period ended March 31, 2025, including the related management's discussion and analysis, and related certifications on or before July 29, 2025 (collectively the 'Annual Financial Filings'). The deadline has now been extended to on or before September 29, 2025. Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files its Annual Financial Filings on or before September 29, 2025, and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.
Globe and Mail
9 hours ago
- Globe and Mail
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK , Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000 . Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000 . The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025 , and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025 , in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Cision Canada
10 hours ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
